Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul;47(7):1733-1741.
doi: 10.1007/s40618-023-02275-1. Epub 2024 Jan 20.

Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up

C Urbani #  1 , F Dassie #  2 , B Zampetti  3 , R Mioni  2 , P Maffei #  4 , R Cozzi #  3 , F Bogazzi #  5
Affiliations
Observational Study

Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up

C Urbani et al. J Endocrinol Invest. 2024 Jul.

Abstract

Objective: Pasireotide LAR (PAS-LAR) was released in Italy in 2017 to treat acromegaly patients resistant to SRLs (Somatostatin Receptors Ligands). The long-term follow-up data of PAS-LAR therapy in Italy are limited. This study aimed to evaluate the efficacy and safety of PAS-LAR in acromegaly.

Design: Patients with acromegaly in PAS-LAR treatment were enrolled in three tertiary Italian endocrinological centers and evaluated by a retrospective observational real-life multicentre study.

Methods: Patients have been studied before (baseline) and 1, 6, 12, 24 and > 36 months after PAS-LAR start. Clinical, biochemical, and pituitary magnetic resonance data were collected, along with information on adverse events. Acromegaly disease activity was classified according to the IGF-1 index (normal value < 1.0).

Results: Fifty patients (female 23) were enrolled. PAS-LAR treatment (mean follow-up 24 ± 16 months) significantly decreased IGF-1 levels (IGF-1 index baseline vs last visit: 1.9 ± 0.6 vs 1.2 ± 0.6, p < 0.0001). At the last visit, 67% of patients had controlled disease, and 44% showed a decrease in tumor volume. Clinical and biochemical efficacy was observed as early as after 1-month of PAS-LAR treatment (IGF-1 index baseline vs 1-month: 1.9 ± 0.6 vs 1.4 ± 0.7, p < 0.0001). Also, 50% of patients referred headache improvement or disappearance. Fifteen patients discontinued PAS-LAR due to failure of treatment and poor glycaemic control. The prevalence of diabetes increased from 33% at the baseline to 54% at the last visit (p = 0.0072).

Conclusion: In real-life settings, PAS-LAR significantly decreases symptoms, IGF-1 levels, and the size of adenoma in patients with acromegaly resistant to SRLs. Beneficial effects may occur early after the first injection.

Keywords: GH; Headache; IGF-1; PAS-LAR.

PubMed Disclaimer

Conflict of interest statement

The authors have not conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Effect of PAS-LAR on IGF-1 index
See this image and copyright information in PMC

References

    1. Cozzi R et al (2020) Italian Association of Clinical Endocrinologists (AME) and Italian AACE chapter position statement for clinical practice: acromegaly - Part 2: Therapeutic Issues. EMIDDT 20(8):1144–1155. 10.2174/187153032066620012911332810.2174/1871530320666200129113328 - DOI - PMC - PubMed
    1. Bolanowski M et al (2022) Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord. 10.1007/s11154-022-09710-3 10.1007/s11154-022-09710-3 - DOI - PMC - PubMed
    1. Gadelha M et al (2020) Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol. 10.3389/fendo.2019.0093110.3389/fendo.2019.00931 - DOI - PMC - PubMed
    1. Petersenn S et al (2014) Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol 54(11):1308–1317. 10.1002/jcph.326 10.1002/jcph.326 - DOI - PubMed
    1. Colao A et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791–799 10.1210/jc.2013-2480 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources